Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > how do the few longs feel about jd leaving you?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Sep 28, 2022 5:53pm
200 Views
Post# 34993427

RE:RE:how do the few longs feel about jd leaving you?

RE:RE:how do the few longs feel about jd leaving you?Thanks, narmac.

I stated my intentions regarding this forum in a previous post.

About today's news regarding Eisai's lecanemab, I debated making some comments but I'm too busy to put the references together and explain their contents. There is nothing about this news that directly affects Bioasis and until full trial results are released, there are no time considerations for us to think about.

This drug, lecanemab (aka BAN2401), will be controversial but it looks like the FDA and the medical insurance industry will accept it. There remain several issues, including only slowed, not arrested, cognitive decline. There are things to discuss about the BBB and Alzheimer's disease as well as how lecanemab behaves in the body. It appears to me that there are opportunities for Bioasis and xB3 with respect to this and/or similar drugs, and with Alzheimer's in and of itself. I also have some thoughts about the upcoming AGM.

I may offer a discussion of these things in private emails or on a private StoxComm website, but not likely on here. I'll let you know.

I continue to support xB3 and its advancement by Bioasis.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities